drugset
Drugs / LVRNA021
last change Aug 2024 re-read 3 minutes ago

LVRNA021

also known as COVID-19 mRNA Vaccine, Bivalent

Messenger RNA (mRNA)

Developed for
COVID-19 · Orthocoronavirinae infectious disease
Investigated by
AIM Vaccine Co., Ltd. · Ningbo Rongan Biological Pharmaceutical Co., Ltd. · The First Affiliated Hospital of Bengbu Medical University · LiveRNA Therapeutics Inc.

Trials 4

today NCT05939596 · Ph 1 NCT05812014 · Ph 3 NCT05547243 · not/applicable NCT05547256 · not/applicable
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05939596 Aug → Sep 2023 Orthocoronavirinae infectious disease AIM Vaccine Co., Ltd. Unknown No outcome recorded
Phase 31 trial
Phase 3 NCT05812014 Mar 2023 → Mar 2024 Orthocoronavirinae infectious disease AIM Vaccine Co., Ltd. Unknown No outcome recorded
Phase not applicable2 trials
— NCT05547243 Sep → Dec 2022 COVID-19 AIM Vaccine Co., Ltd. Unknown No outcome recorded
— NCT05547256 Sep → Dec 2022 COVID-19 AIM Vaccine Co., Ltd. Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as LVRNA021 “A Cohort Study to Evaluate Safety and Immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in Participants Aged 18 Years and Over in China” NCT05547243 ↗
3

“SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)” NCT05939596 ↗

“COVID-19 mRNA Vaccine, Bivalent (LVRNA021)” NCT05547256 ↗

NCT05812014 ↗
Known as COVID-19 mRNA Vaccine, Bivalent “This is a cohort study to evaluate safety and immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in participants aged 18 years and over in China” NCT05547243 ↗
1

“COVID-19 mRNA Vaccine, Bivalent (LVRNA021)” NCT05547256 ↗
Modality Messenger RNA (mRNA) “COVID-19 mRNA Vaccine, Bivalent (LVRNA021)” NCT05547243 ↗
Route Intramuscular “intramuscular injection” NCT05547256 ↗